Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases.

Jonatan Barrera-Chimal, Benjamin Bonnard, Frederic Jaisser

Annual review of physiology 2022 Feb 10

filter terms:

Mineralocorticoid receptor (MR) activation in the heart and vessels leads to pathological effects, such as excessive extracellular matrix accumulation, oxidative stress, and sustained inflammation. In these organs, the MR is expressed in cardiomyocytes, fibroblasts, endothelial cells, smooth muscle cells, and inflammatory cells. We review the accumulating experimental and clinical evidence that pharmacological MR antagonism has a positive impact on a battery of cardiac and vascular pathological states, including heart failure, myocardial infarction, arrhythmic diseases, atherosclerosis, vascular stiffness, and cardiac and vascular injury linked to metabolic comorbidities and chronic kidney disease. Moreover, we present perspectives on optimization of the use of MR antagonists in patients more likely to respond to such therapy and review the evidence suggesting that novel nonsteroidal MR antagonists offer an improved safety profile while retaining their cardiovascular protective effects. Finally, we highlight future therapeutic applications of MR antagonists in cardiovascular injury.

Citation

Jonatan Barrera-Chimal, Benjamin Bonnard, Frederic Jaisser. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annual review of physiology. 2022 Feb 10;84:585-610